by Truveta Research | Dec 14, 2024 | Research, Research Insights
First-time amphetamine/dextroamphetamine prescription rates remained stable overall, but increased significantly for people 30-44, 45-64, and 65+ years of age. The percentage of prescriptions filled within 5 days of being written reached their lowest values in March...
by Truveta Research | Dec 11, 2024 | Research, Research Insights
The rate of first-time ADHD diagnoses has increased since 2021. The largest increases in first-time ADHD diagnosis rates were seen in the 30-44-year-old and 45-64-year-old age groups. Age groups under 30 years old did not see increases in first-time ADHD diagnosis...
by Truveta staff | Dec 6, 2024 | Data
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and...
by Truveta staff | Nov 7, 2024 | Data
GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. First discovered forty years ago, GLP-1 receptor agonists were initially approved for type 2 diabetes in 2005, with the first weight-loss-specific approval following in 2014. Flash...
by Truveta staff | Nov 4, 2024 | Research
Citation: Shaukat, Aasma MD, MPH et al. Real-World Adherence to Repeat Testing for Stool-Based Non-Invasive Colorectal Cancer Screening Tests Among Individuals With Average Risk. The American Journal of Gastroenterology 119(10S):p S265-S266, October...
